Daratumumab

Daratumumab is a monoclonal antibody targeting CD38, a protein highly expressed on the surface of multiple myeloma cells. It works by inducing cell death through immune-mediated mechanisms and direct apoptosis, making it a valuable treatment in oncology. Its relevance to longevity and health optimization lies in its potential to modulate the immune system and target cancerous cells, although its primary use is currently in cancer therapy.